Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen Is Attractively Valued

Abbott Labs

Sanofi

These companies are trying for coronavirus success -- but their commercialized products offer revenue no matter what.

3 Coronavirus Stocks to Buy Now

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Earnings Expected to Grow: Should You Buy?

AbbVie

Novartis

These three stocks aren't just surviving the coronavirus storm -- they're thriving in it.

3 Dividend Stocks Weathering the Coronavirus Storm

Johnson & Johnson

Which stock wins in a battle between these two healthcare giants?

Better Buy: Amgen vs. Johnson & Johnson

Amgen A Buy On Otezla Revenue

Discover how much money investors made from Amgen during its initial public offering (IPO).

If You Had Invested Right After Amgen's IPO (AMGN)

Cigna

CVS Health

UnitedHealth Group

As the world and the markets continue to grapple with the effects of the novel coronavirus outbreak, these innovative healthcare stocks to buy look poised for success.

4 Healthcare Stocks to Buy For Coronavirus Innovation

BWX Technologies

Citrix Systems

Oracle

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

4 GARP Stocks to Scoop Up for  Maximum Returns

Cardinal Health

Costco

Enphase Energy

LogMeIn

Netflix

Coronavirus outbreak-induced global lockdowns are making recession inevitable. Here are six recession-resistant stocks including Netflix (NFLX) to beat COVID-19 induced recession woes.

6 Recession-Proof Picks Amid Coronavirus-Led "The Great Lockdown"

Amgen outperformed the market in 2008; can the company do the same in today's recessionary conditions?

1 Stock That Crushed the Market During the Last Recession

Bristol-Myers

Gilead Sciences

Merck

Track the latest trends and leading stocks in the biotech and pharmaceutical industries.

Biotech Stocks To Watch And Pharma Industry News

Amgen (AMGN) is running into resistance at its historically bearish 160-day moving average

Technical Trouble Could Stop Drug Stock In Its Tracks

Amgen stock is facing concerns that biosimilars could chip away at some of its biggest moneymakers. Is it time to buy shares of the biotech company?

Biotech Giant Amgen Entered The Coronavirus Arena — But Is It A Buy?

Canadian Pacific Kansas City Limited

Copart

Intel

With market valuations tumbling near three-year lows as the Covid-19 virus outbreak rattles markets around the globe, GuruFocus Editorial Assistant James Li discusses how investors can seek good opportunities based on Berkshire Hathaway Inc.

Video: 4 Large-Cap Stocks With Strong Buffett-Munger Characteristics

Adaptive Biotechnologies

Despite a potential vaccine, the novel coronavirus could return on a seasonal basis, much like the flu, according to Seattle-based company Adaptive Biotechnologies.

Adaptive Biotech’s deal with Amgen influenced by belief that COVID-19 may return seasonally, like flu

Incyte

Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.

Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In

Eli Lilly

V&M Breakouts: Top Growth And Dividend Stocks For April 2020

Amgen, Inc. (NASDAQ: AMGN) shares are trading higher on Thursday, after the company and Adaptive announced they will partner to develop a coronavirus therapeutic.

Why Amgen's Stock Is Trading Higher  Today

Amgen was one of the few blue chip stocks to post a gain during the month of March. Here's why.

Why Amgen Stock Sailed Through March Without a Scratch

The two biotechs aren't wasting any time getting their new joint COVID-19 effort up and running.

Amgen Teams Up With Adaptive Biotechnologies to Develop COVID-19 Therapy

Pharmaceutical giant Amgen is aiming to develop a new drug to treat and prevent COVID-19, using insights from Seattle-based Adaptive Biotechnologies’ system for sequencing the human immune system, under an expanded partnership announced by the companies Thursday morning.

The search for a COVID-19 cure: Amgen and Adaptive Biotech partner in quest for new drug

Shares of Amgen Inc. AMGN, -0.17% gained 1.2% in trading on Thursday after the drugmaker announced that it is collaborating with Adaptive Biotechnologies Corp.

Amgen, Adaptive Biotechnologies ink COVID-19 antibody development collaboration

The COVID-19 pandemic has led the big biotech to join many of its peers in making timeline-altering drug study adjustments.

Amgen Pauses Some Clinical Trials to Reduce Coronavirus Transmission Risk

Amgen shares moved higher during Monday's session after Raymond James upgraded the stock to Outperform with a $255 price target.

News for Amgen Stock (AMGN)